Clinical trials: Maculopathy, open to volunteers
Geographic Atrophy, Age - Related Macular Degeneration (AMD)
An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy
The goals of this interventional study are (1) to evaluate the safety and tolerability of multiple doses of PST-611 in men and women over the age of 65 with geographic atrophy secondary to age-related macular degeneration and (2)…
- Trial name
- NCT07705568
- Testing
- PST-611
- Where
- 3 sites in France
- Volunteers
- 24 people
- Sponsor
- Eyevensys
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Intermediate AMD
A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD
The proposed clinical investigation wants primary to validate the safety of the innovative light therapy approach and in second priority provide insight and confirmations on therapeutic effect.
- Trial name
- retinaSEES-PoC (NCT06557369)
- Testing
- reSEES
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Oculox Technologies SA
Neovascular Age-related Macular Degeneration
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
- Trial name
- NCT06141460
- Testing
- RRG001
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Refreshgene Technology Co., Ltd.
Dry Age-related Macular Degeneration, Geographic Atrophy
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea.
- Trial name
- PATCH-AMD (NCT06557460)
- Testing
- Surgical implantation of the CPCB-RPE1 implant
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regenerative Patch Technologies, LLC
Geographic Atrophy
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study aims to evaluate the safety and efficacy of BRX011, an oral medication, taken once daily by participants with geographic atrophy secondary to age-related macular degeneration.
- Trial name
- BELLAVISTA (NCT07029945)
- Testing
- BRX011
- Where
- 17 sites in United States, Australia
- Volunteers
- 152 people
- Sponsor
- Biojiva LLC
Geographic Atrophy of the Macula
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina.
- Trial name
- eDREAM (NCT06659549)
- Testing
- GAL-101
- Where
- 24 sites in United States, Armenia and 6 more
- Volunteers
- 110 people
- Sponsor
- Galimedix Therapeutics Inc
Age-Related Macular Degeneration
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of…
- Trial name
- NCT03178149
- Testing
- ASP7317, tacrolimus, trimethoprim-sulfamethoxazole
- Where
- 20 sites in United States
- Volunteers
- 42 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Neovascular Age-related Macular Degeneration
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina.
- Trial name
- NCT07007065
- Testing
- Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
- Where
- 138 sites in United States, Austria and 15 more
- Volunteers
- 561 people
- Sponsor
- AbbVie
Retinal Dystrophies, Color Vision Defects
Natural History Study of Inherited Retinal Diseases
This prospective, observational investigation seeks to delineate the interplay between chromatic vision deficits and both functional visual outcomes and anatomical retinal biomarkers in individuals affected by Inherited Retinal…
- Conditions
- Retinal Dystrophies, Color Vision Defects, Vision Disorders, Macular Degeneration
- Trial name
- MojiLVCDT (NCT07085533)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Augelux Therapeutics
nAMD
A Study to Compare GNR-139 and Eylea® in Patients With nAMD
This is a multicenter, randomized, double-blind study designed to compare the efficacy and safety of the investigational drug GNR-139 with the reference drug Eylea in treatment-naive patients with neovascular age-related macular…
- Trial name
- NCT07844148
- Testing
- aflibercept, Eylea
- Where
- 14 sites in Russia
- Volunteers
- 180 people
- Sponsor
- AO GENERIUM
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary…
- Trial name
- VISION (NCT06765980)
- Testing
- VV-14295
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 62 people
- Sponsor
- Kriya Therapeutics, Inc.
ROSAH
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
- Trial name
- NCT06395285
- Testing
- DF-003
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 12 people
- Sponsor
- Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Age-Related Macular Degeneration, Geographic Atrophy
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage…
- Trial name
- CONCERTO (NCT05438732)
- Testing
- smaller incision, new generation implantable miniature telescope (SING-IMT)
- Where
- 10 sites in United States
- Volunteers
- 125 people
- Sponsor
- VisionCare, Inc.
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
This is a non-interventional, observational study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years.
- Trial name
- Pre-GAIN (NCT07144137)
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Complement Therapeutics
Geographic Atrophy Secondary to Age-related Macular Degeneration
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
Geographic atrophy (GA) is a progressive eye disease that causes the degeneration of the retinal cells, particularly in the macula, leading to vision loss.
- Trial name
- TES-GAP (NCT07531927)
- Testing
- Transcorneal electrical stimulation (TES) with the OkuStim 2 System
- Where
- 5 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Okuvision GmbH
ARB, BVMD
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
The goal of this clinical trial is to learn if drug OPGx-BEST1 works to treat BVMD and ARB Bestrophinopathy. It will also learn about the safety of drug OPGx-BEST1.
- Conditions
- ARB, BVMD, Autosomal-Dominant Bestrophinopathy, Best Vitelliform Macular Dystrophy
- Trial name
- BIRD-1 (NCT07185256)
- Testing
- OPGx-BEST1
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Opus Genetics, Inc
Geographic Atrophy
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.
- Trial name
- AiiM OLE (NCT07807969)
- Testing
- Vonaprument
- Where
- 7 sites in United States
- Volunteers
- 605 people
- Sponsor
- Annexon, Inc.
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that…
- Trial name
- NCT07308639
- Testing
- anti-VEGF medication
- Where
- Germany
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD.
- Trial name
- NCT05986864
- Testing
- SKG0106
- Where
- 9 sites in United States, China
- Volunteers
- 68 people
- Sponsor
- Skyline Therapeutics (US) Inc.